Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

USA News GroupNews Commentary – Despite optimism coming from the launch of Project Stargate (a $500 billion investment in AI ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Biotech continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology ...

Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven ...

Oncolytics Biotech Inc shares T.ONC are trading unchanged at $1.07.

SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a $24.63 billion market cap biotechnology company specializing in cancer immunotherapy, has announced ...

Oncolytics (ONCY) reported on progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep’s potential in ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – Amid the excitement surrounding Project Stargate-the $500 billion ...

Issued on behalf of Oncolytics Biotech Inc. "We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year," said Wayne Pisano ...